

22nd May, 2025

To,
The Manager - Corporate Relationship
Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Limited
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

BSE Scrip Code: - 524500

NSE SYMBOL: - KILITCH

Sub: Press Release

Dear Sir,

Please find enclosed herewith our Press Release relating to Q425 financial results of the Company, which we shall be releasing after sending this letter to you.

Request you to take note of the same and acknowledge the receipt.

Thanking you,

Yours' Faithfully,

For **Kilitch Drugs (India) Limited**

Mukund Mehta
Managing Director
DIN: 00147876





Kilitch Drugs Limited Q4FY25 PAT registers 212% YoY remarkable growth and Revenue from operations rises by 44 % on Standalone Basis

May 2025, Mumbai - Kilitch Drugs Limited, BSE and NSE listed, a leading pharmaceutical company specializing in the manufacturing and distribution of high-quality Parenteral, Injectables, Oral Solids, and Effervescent, announced its unaudited financial results for the quarter ended on 31 March 2025

The company's reported a 178% per cent year-on-year(Y-o-Y) remarkable rise in consolidated profit after tax (PAT) for the Q4 FY25 to Rs. 1,021.86 lakh from Rs. 368.07 lakh for the corresponding period previous year.

The company recorded its quarterly consolidated revenue from operations at Rs. 6,122.58 lakh in Q4FY25, experiencing 37 per cent of Y-o-Y excellence growth from Rs. 4,481.88 lakh in Q4FY24. The growth is achieved by continuous efforts to meet steady demand across globe and will continue further.

Consecutively, the company's standalone PAT rose by 212%% per cent, and revenue grew by 44% per cent to Rs 1,137.41 lakh and Rs 18,158.73 lakh recorded in Q4 FY25, respectively.

For the year ending March 2025, In FY25, Kilitch reported an over 77 percent YoY rise in standalone net profit to ₹ 3,115.69 lakh, compared to ₹ 1,757.38 lakh in FY24. The Standalone Revenue from operation for the period increased by 38 percent to ₹Rs 18,158.73 lakh from ₹Rs 13,159.90 lakh in the previous year.

Commenting on the Q4FY25 performance, Mr. Mukund Mehta, the Managing Director of Kilitch Drugs said, "We witnessed significant growth in our performance for this year; revenue from operations grew by 44% and PAT increased by 212% on standalone basis as compared to Q4FY2024. We remain focused on driving sustainable growth and delivering strong returns for our stakeholders."

About Kilitch Drugs (India) Ltd:

Incorporated in 1992, Kilitch Drugs (India) Ltd is a leading pharmaceutical manufacturing company with existing manufacturing units in Mumbai, India, Ethiopia (Africa) and setting up a new green field project in Pen, Maharashtra India, which aims to develop and manufacture various pharmaceuticals including Injectables, Ophthalmic, OSD and Nutraceuticals, meeting regulatory requirements along with USFDA to approach across the globe. The company is a global innovator and has been consistently recognized for its excellence in quality, innovative processes, research and development, and sustainable product portfolio. Kilitch Drugs India Ltd has successfully established a foothold across several key African countries. Its manufacturing plant in Mumbai is equipped with specialized sections for dry powder formulations, small-volume liquid ampoules, and vials. The company's facilities are certified by multiple global authorities, including WHO GMP, ISO 9001, ISO 13485, PPB Kenya, NAFDAC Nigeria, FDA Ghana, MOH Sudan, Phillipines Pix Approvals, EFDA Ethiopia and many other countries. The company's product portfolio spans a wide range of therapeutic areas, including gastroenterology, anti-inflammatory, anti-malarial, ophthalmic, uterine stimulants, veterinary medicines, and many more

For media queries, please contact:

Meeral Salia	Rehan Khan
M: +91 77383634559	M: +91 9511265893
E: meeral.s@sgal.net	E: rehan.khan@sgapl.net